C
DGX icon

Cerebellum’s Quest Diagnostics DGX Stock Holding History

Cerebellum’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$64K Sell
560
-741
-57% -$87.5K 0.3% 123
2020
Q2 		$128K Buy
+1,301
New +$138K 0.09% 166
2019
Q4 		– Sell
-1,227
Closed -$131K – 452
2019
Q3 		$131K Buy
+1,227
New +$126K 0.08% 371
2018
Q4 		– Sell
-1,082
Closed -$117K – 466
2018
Q3 		$117K Sell
1,082
-572
-35% -$62.7K 0.19% 339
2018
Q2 		$182K Sell
1,654
-194
-10% -$20.2K 0.31% 34
2018
Q1 		$185K Buy
1,848
+547
+42% +$56K 0.24% 194
2017
Q4 		$128K Buy
+1,301
New +$123K 0.09% 166

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $7.03B AUM 11.68% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Cerebellum's DGX Position: Q3 2020 in Review

Cerebellum reduced its Quest Diagnostics (DGX) stake by 57% in Q3 2020, selling an estimated $87.5K and leaving 560 shares worth $64K. The position accounts for 0.3% of the portfolio, ranked #123.

Cerebellum first reported a position in DGX in Q4 2017 and has held it in 7 quarters since. The position peaked at $185K in Q1 2018. 758 funds tracked by Wall St. Rank hold DGX as of Q3 2020.

  • Cerebellum held 560 shares of Quest Diagnostics worth $64K as of Q3 2020.
  • Cerebellum sold 741 Quest Diagnostics shares in Q3 2020, an estimated $87.5K.
  • Quest Diagnostics made up 0.3% of Cerebellum's portfolio in Q3 2020, its #123 holding.
  • Cerebellum first reported a position in Quest Diagnostics in Q4 2017 and has held it in 7 quarters since.
  • Cerebellum's Quest Diagnostics position peaked at $185K in Q1 2018.
  • 758 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2020.

Based on Cerebellum's 13F filing for Q3 2020, filed 21 Oct 2020.